Pfizer (PFE) Offering Possible 20.19% Return Over the Next 24 Calendar Days

Pfizer's most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $47.00 short put and a strike $42.00 long put offers a potential 20.19% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $47.00 by expiration. The full premium credit of $0.84 would be kept by the premium seller. The risk of $4.16 would be incurred if the stock dropped below the $42.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.

The RSI indicator is at 68.09 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Pfizer

UPDATE 1-Thailand to receive 61 mln doses of AstraZeneca vaccine this year
Mon, 23 Aug 2021 11:48:06 +0000
Thailand will receive 61 million doses of the AstraZeneca COVID-19 vaccine this year, a government spokesperson said on Monday, as the Southeast Asian country rushes to vaccinate its population amid a surge in coronavirus infections. Thailand is AstraZeneca's COVID-19 vaccine manufacturing hub for the region, but has been slow to obtain enough shots to inoculate its population. About 9% of Thailand's 66 million people have been fully vaccinated.

Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion
Mon, 23 Aug 2021 11:04:15 +0000
Shares of Trillium Therapeutics Inc. nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an agreement to be acquired by Pfizer Inc. in a cash deal valued $2.26 billion. Under terms of the agreement, Pfizer will pay $18.50 for each Trillium share it doesn't already own, which is 203.8% above Friday's closing price of $6.09. Pfizer's stock rose 4.0% ahead of the open. “The proposed acquisition of Trillium builds on our strong track record of

Pfizer to buy Trillium Therapeutics in $2.26 billion deal
Mon, 23 Aug 2021 10:55:57 +0000
Pfizer, which acquired a $25 million stake in Trillium last year, will buy the remaining outstanding shares for $18.50 a piece, representing a 203.8% premium to the stock's last closing price. Canada-based Trillium is developing drugs that boost patients' innate immune system to detect and destroy cancer cells. Pfizer's financial adviser for the transaction is BofA Securities Inc, and Centerview Partners LLC is Trillium's.

Coronavirus tally: Average daily U.S. death toll tops 1,000 for first time in 5 months, FDA set to approve Pfizer vaccine
Mon, 23 Aug 2021 10:51:10 +0000
The global tally for the coronavirus-borne illness climbed to 211.9 million as of early Monday, while death toll rose to 4,432,694, according to

Pfizer to Acquire Trillium Therapeutics Inc.
Mon, 23 Aug 2021 10:45:00 +0000
Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives NEW YORK and CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today an

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.